| Cat.No. | Name | Information |
|---|---|---|
| M8959 | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) | BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM. |
| M6101 | Atezolizumab | Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. MW: 145 KD. atezolizumab reacts with murine PD-L1 (for human and non-humanized mice). |
| M3813 | Avelumab (MSB0010718C) | Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1 |
| M6100 | Nivolumab | Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). |
| M45219 | ABSK043 | ABSK043 is a potential best-in-class (BIC), orally active small molecule inhibitor of PD-L1 for studies related to solid tumors. |
| M42034 | PD-1/PD-L1-IN-33 | PD-1/PD-L1-IN-33 is a PD-1/PD-L1 inhibitor. |
| M42033 | PD-1/PD-L1-IN-31 | PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). |
| M42032 | PD1-PDL1-IN 1 TFA | PD1-PDL1-IN 1 TFA is a potent programmed cell death 1 (PD-1) inhibitor. |
| M42031 | PD-L1-IN-2 | PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. |
| M42030 | PD-1/PD-L1-IN-32 | PD-1/PD-L1-IN-32 is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. |
| M42029 | PD-L1-IN-3 | PD-L1-IN-3 is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. |
| M41724 | LSD1-IN-27 | LSD1-IN-27 is a LSD1 inhibitor (IC50: 13 nM). |
| M40594 | Genolimzumab | Genolimzumab is a PD-1 monoclonal antibody that can be used in studies related to peripheral T-cell lymphoma (PTCL). |
| M31383 | CLP-002 | CLP-002 is a low molecular weight anti-PD-L1 short peptide inhibitor, which can act by blocking the interaction between pd-1 and pd-l1, and thus can be used in tumor related studies. Sequence: WHRSYYTWNLNT |
| M31308 | IMMH-010 | IMMH-010 is a potent prodrug of the programmed cell death ligand 1 (PD-L1) inhibitor YPD-29B for studies related to oncology and neurological diseases. |
| M31307 | MAX-10181 | MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor with an IC50 value of 0.018 μM.It can be used in studies related to solid tumors. |
| M31306 | LH1307 | LH1307 is a C2-symmetric small molecule inhibitor of PD-1:PD-L1 interactions. |
| M31305 | LH1306 | LH1306 is a small molecule inhibitor of C2 symmetric PD-1:PD-L1 interactions. |
| M31303 | BMS-200 | BMS-200 is a small molecule inhibitor that targets PD-L1 and promotes PD-L1 dimerization. |
| M31302 | BMS-37 | BMS-37 is a diaryl ether small molecule and a PD-1/PD-L1 immune checkpoint inhibitor. In addition, BMS-37 can also act as a PD-L1 ligand to synthesize PROTAC molecules. |
| M31224 | BMSpep-57 | BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs. |
| M31046 | Human PD-L1 inhibitor V TFA | Human PD-L1 inhibitor V TFA, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1. |
| M31045 | PD1-PDL1-IN 1 TFA | PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator. |
| M31044 | PD-1/PD-L1-IN 3 TFA | PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
